The CCB Program Area has 24 core members, distributed among these three focus areas. During the current funding year, peer-reviewed funding totaled $12 million in total costs, including $1.45 million from the National Cancer Institute. As with other Program Areas, JCCC fosters a number of interactive activities and many of the Shared Resources that support investigators in the CCB Program Area. During the current grant cycle, funds from the JCCC in the form of CCSG Developmental Funds, institutional support and philanthropic gifts to the CCB Program Area total $1,042,520. These funds supported Interdisciplinary Grants, Seed Grants, recruitment/retention, Program Area Leadership support, funding for the use of emerging Shared Resources and trainees. Twelve of the Program Area Members were the recipients of JCCC support. Cancer Cell Biology Program Area members published 201 peer-reviewed papers during the recent five-year renewal period. The JCCC CCB program area is highly interactive, with 9% of its 201 publications reflecting intraprogrammatic efforts and 59% reporting inter-programmatic collaborations. 129 publications (64%) appeared in high-impact journals. The Cancer Cell Biology (CCB) Program Area was previously named the """"""""Molecular, Cellular and Developmental Biology (MCDB) Program Area."""""""" In response to the 2002 CCSG review, and in extensive consultation with our External Advisory Board, the JCCC has reorganized this program. The goals of the reorganization were to: (1) identify critical cancer-relevant focus areas of basic science and biomedical technologies;(2) identify appropriate leaders and members for these focus areas;(3) promote intraprogrammatic interactions and collaborations within and across these groups in cancer-related areas;and (4) foster inter-programmatic interactions leading to translational and clinical collaboration. Concomitantly with the interest in reorganizing this program area, UCLA had made the strategic decision to invest heavily in infrastructure, faculty recruitment and funding in nanotechnology and stem cell biology;the California NanoSystems Institute and the Broad Stem Cell Center (BSCC) have both been created during the current JCCC CCSG funding cycle, and new buildings constructed to house these programs. The JCCC capitalized and incorporated the investment made by UCLA into our Program Area strategic plan and identified three main interest groups for the Cancer Cell Biology Program Area: (1) nanobiology applications to cancer detection, monitoring, and therapy;(2) cancer stem cell identification and eradication;and (3) model organism studies of cancer detection, progression, and therapy. Senior Associate Dean Dr. Leonard Rome, the former MCDB Program Area director, has become the JCCC Director for Strategic Planning and Partnerships. With the enthusiastic support of our EAB, Dr. Luisa Iruela-Arispe, an internationally known developmental biologist and cancer researcher has become the Director of the CCB Program Area. Dr. Michael Teitell, a pathologist and cancer biologist with strong interests in nanotechnology, brings strength in this area and a clinical perspective to the Co-Director position.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016042-35
Application #
8010896
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2009-12-01
Budget End
2010-11-30
Support Year
35
Fiscal Year
2010
Total Cost
$59,018
Indirect Cost
Name
University of California Los Angeles
Department
Type
DUNS #
092530369
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Tsang, Eric J; Wu, Benjamin; Zuk, Patricia (2018) MAPK signaling has stage-dependent osteogenic effects on human adipose-derived stem cells in vitro. Connect Tissue Res 59:129-146
Waters, Lynnea R; Ahsan, Fasih M; Wolf, Dane M et al. (2018) Initial B Cell Activation Induces Metabolic Reprogramming and Mitochondrial Remodeling. iScience 5:99-109
Van Dyk, Kathleen; Bower, Julienne E; Crespi, Catherine M et al. (2018) Cognitive function following breast cancer treatment and associations with concurrent symptoms. NPJ Breast Cancer 4:25
Robinett, Ryan A; Guan, Ning; Lux, Anja et al. (2018) Dissecting Fc?R Regulation through a Multivalent Binding Model. Cell Syst 7:41-48.e5
Chin, Chee Jia; Li, Suwen; Corselli, Mirko et al. (2018) Transcriptionally and Functionally Distinct Mesenchymal Subpopulations Are Generated from Human Pluripotent Stem Cells. Stem Cell Reports 10:436-446
Alban, Tyler J; Alvarado, Alvaro G; Sorensen, Mia D et al. (2018) Global immune fingerprinting in glioblastoma patient peripheral blood reveals immune-suppression signatures associated with prognosis. JCI Insight 3:
Yang, Qing; Fung, Wing K; Li, Gang (2018) Sample size determination for jointly testing a cause-specific hazard and the all-cause hazard in the presence of competing risks. Stat Med 37:1389-1401
Seo, Jai Woong; Tavaré, Richard; Mahakian, Lisa M et al. (2018) CD8+ T-Cell Density Imaging with 64Cu-Labeled Cys-Diabody Informs Immunotherapy Protocols. Clin Cancer Res 24:4976-4987
Ribas, Antoni; Wolchok, Jedd D (2018) Cancer immunotherapy using checkpoint blockade. Science 359:1350-1355
Wang, Hong; Chen, Xiaolin; Li, Gang (2018) Survival Forests with R-Squared Splitting Rules. J Comput Biol 25:388-395

Showing the most recent 10 out of 767 publications